Navigation Links
International Rett Syndrome Foundation awards $2M for cutting-edge Rett syndrome research
Date:10/1/2009

, PhD
Alfred I. DuPont Hospital for Children/Nemours Children's Clinic at the University of Delaware Preclinical testing of nonsense suppression in a rodent model of Rett syndrome

Dr. Schanen has previously developed mouse "knock-in" models of the R168X and R255X non-sense Rett syndrome mutations. The project will further generate colonies of the two knock-in mouse models and ultimately the new mouse models will be used to test a lead series of read-through compounds. The successful testing of these drugs could potentially result in a pharmacological reversal of Rett syndrome. This study would have an enormous impact upon the field and has clear implications for treatment of the disease.

Yi Eve Sun PhD, University of California at Los Angeles, David Geffen School of Medicine
The role of microRNA dysregulation in MeCP2-deficient neurons

The field of epigenetics has recently identified a set of small molecules called "micro-RNAs." These are thought to be critically important regulators that fine tune and modulate the function of different proteins and essential cellular processes. The aim of this project is to test the novel hypothesis that MeCP2 might regulate different sets of "micro-RNAs" in different neuronal subsets within the brain and which may have functional consequences as a whole. The proposal by Dr. Sun presents a clear set of experiments that will further our understanding of the basic mechanisms underlying Rett syndrome and could identify novel targets for therapeutic manipulation.

John Vincent PhD, The Centre for Addiction & Mental Health, University of Ottawa
Comparative Functional Studies Of The Two MeCP2 Isoforms, MeCP2_e1 and MeCP2_e2

This is a research proposal that aims to address the important question of which of the two common forms of MECP2 is most critical for brain development and function in the mouse. This is an interesting proposal that addresses a key as
'/>"/>

Contact: Dr. Antony Horton
212-459-2608
International Rett Syndrome Foundation
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology news :

1. International conference on endothelin
2. International event brings worlds top cancer doctors to Queens
3. Forest Service to host 2nd International Conference on Forests and Water in a Changing Environment
4. EMBO pioneers pension plan for internationally mobile postdoctoral researchers
5. International conference on CO2 sequestration processes
6. International research team seeks to unravel flatworm regeneration
7. Fujitsu PalmSecure Certified Under International Common Criteria Evaluation Assurance Level 2
8. Journal of Vascular and Interventional Radiology increases impact, international reach
9. International team of students and scientists on month-long field course in Siberian Arctic
10. ESHRE launches international study of polar body screening
11. International collaboration by scientists culminates in novel ion channels database
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market is ... utilize more than one characteristic of an individual for ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans for ... Funding for this $50 million capital project is part of ... summer. The medical education building will be ... complex, adjacent to 525@vine in Wake Forest Innovation Quarter. Construction ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... -- A new calibration tool was recently developed to help ... the correct amount of pressure. C.A. Seybold and colleagues, ... 2009 issue of Journal of Natural Resources and Life ... the strength of a soil to withstand an applied stress ...
... is the difficulty of aiming these treatments at destroying ... But a new study by McMaster University researchers has ... drugs that more carefully target cancer, while sparing normal ... McMaster Stem Cell and Cancer Research Institute in the ...
... Salk Institute for Biological Studies have developed a versatile ... cancer in humansthat closely resembles the development and progression ... "Mouse models of human cancer have taught us a ... says Inder Verma, Ph.D., a professor in the Laboratory ...
Cached Biology News:Describing soils: Calibration tool for teaching soil rupture resistance 2Scientists can now differentiate between healthy cells and cancer cells 2Salk researchers develop novel glioblastoma mouse model 2Salk researchers develop novel glioblastoma mouse model 3
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... 22, 2015 Crystal Diagnostics (CDx) Xpress System, ... has received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing ... collectively referred to as STEC or the “Big-6”) as well ... unit (cfu) per 325 g of raw ground beef and ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... ST. LOUIS, April 22 , HIGHLIGHTS: 2008 Results (all percentage comparisons are ... New Quarterly Record: Q1 2008 sales reached a new ... four business units also achieving new quarterly ... the quarter. Organic sales growth of ...
... RESEARCH TRIANGLE PARK, N.C., April 22 ... three new practice,leaders and a business development ... business, which provides pharmaceutical, biotech and medical,device ... and minimize,risk from early discovery through commercialization., ...
... Biodel Inc. (Nasdaq:,BIOD) today announced that Dr. Solomon Steiner, ... at the Morgan Stanley Global Healthcare,Unplugged Conference on Wednesday, ... will be held at the Ritz-Carlton Key Biscayne in ... to a live webcast of the corporate,presentation in the ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 2Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 3Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 4Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 5Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 6Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 7Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 8Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 9Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 10Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 11Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 12Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 13Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 14Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 15Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 16Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 17Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 18Quintiles Consulting Business Expands 2Quintiles Consulting Business Expands 3Quintiles Consulting Business Expands 4
... efficient delivery of siRNA while maintaining high ... to 96 samples simultaneously , ... harvest to post-electroporation incubation , ... Designed for use with the Bio-Rad ...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: